The number of more complex biopharmaceuticals in development continues to increase and some of these include molecules that require multiple proteins to be expressed at differing ratios to produce the correct biopharmaceutical. In this article, the authors outline cell-line development and process scale-up for an antibody program in which the antibody requires additional processing by a site-specific enzyme for correct functionality.
With the rising interest in biopharmaceuticals, drug developers need to quickly understand and evaluate the binding of therapeutic antibodies to Fc receptors. Learn how a new analytical testing panel that uses an Octet-based Fc receptor panel may help developers achieve a faster assessment of monoclonal antibody functionality — well before the final molecule is selected.
Shortening timelines to generate more productive, stable, and high expressing cell lines is the goal of any cell line development program. This technical poster details the methodologies and clonal variation of combining a cell line development technology with a platform for clonal cell line selection.
Catalent in-house pharmaceutical sourcing specialists utilize a global network of leading manufacturers, wholesalers, and carefully selected QA-qualified healthcare professionals to provide cost-effective access to virtually any product. When you use Catalent for pharmaceutical sourcing you get a global distribution network that can deliver what you need, where you need it, and when you need it. Always in the right condition.